HE4 With ROMA Index

Ovarian cancer is one of the most common gynecological cancers in women. Early detection of ovarian cancer can be challenging due to its non-specific symptoms often mistaken for other conditions. This highlights the importance of early detection and advanced diagnostic tests like the HE4 With ROMA Index test.

The HE4 With ROMA Index test is not intended as a screening or standalone diagnostic test. It should be used in combination with other diagnostic tools like imaging, biopsies, etc., as well as clinical evaluation for confirmatory diagnosis of ovarian cancer. This test combines the measurement of HE4, a protein that is produced by cells in the ovaries and the lining of the respiratory tract, often elevated in epithelial ovarian cancer, and CA 125, a protein that can be elevated in ovarian cancer and other physiological or pathological conditions such as menstruation, pregnancy, endometriosis, uterine fibroids, and pelvic inflammatory disease. 

The ROMA index is a mathematical formula that combines the levels of HE4 and CA 125 with menopausal status (defined as the absence of periods for 12 months in a row) to estimate ovarian cancer risk, categorizing women with an adnexal mass into high-risk or low-risk groups, and enhances accuracy in early detection. ROMA is not a definitive indicator of cancer presence or absence and is not intended for general cancer screening. However, a low-risk ROMA result should not rule out an oncologist (a doctor who specializes in diagnosing and treating cancer) referral if the initial cancer risk is high. Additionally, ROMA has not been validated for patients previously treated for cancer, undergoing chemotherapy, or below 18 years of age.

The HE4 With ROMA Index test is specifically recommended for women above 18 years of age having adnexal masses planned for surgery and who have not yet been referred to an oncologist. This test is not suitable for monitoring mucinous or germ-cell ovarian cancer. It offers a more nuanced assessment of ovarian cancer risk, particularly distinguishing between malignant (cancerous) and benign (non-cancerous) ovarian masses. 

No special preparation is required for this test. However, a brief clinical history or doctor's prescription should be provided during sample collection. Additionally, indicate the date of your last menstrual period (LMP) or menopausal status. Inform your doctor about any medications or supplements you may be taking, as these could impact the test results. 

Don't self-medicate at home solely based on the test results, and always consult a doctor for a proper understanding of your health needs.

Please note: This is an outsourced test. The sample for this test is collected by TATA 1MG and processed at a NABL accredited partnered lab.